-CuraSen Therapeutics Announces Strategic Investment from the Alzheimer's Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer's Disease

Press/Media

Period10 Oct 2023

Media coverage

2

Media coverage

  • Title-CuraSen Therapeutics Announces Strategic Investment from the Alzheimer's Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer's Disease
    Media name/outletM2 PressWIRE
    Country/TerritoryUnited States
    Date10/10/23
    PersonsHoward Fillit
  • Title-CuraSen Therapeutics Announces Strategic Investment from the Alzheimer's Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer's Disease
    Media name/outletENP Newswire
    Country/TerritoryUnited Kingdom
    Date10/10/23
    PersonsHoward Fillit